VivoSeq
Infectious Disease

Neonatal Sepsis

15

Pipeline Programs

2

Active Trials

10

Companies Involved

Neonatal sepsis is an emerging landscape with 15 programs across 10 companies. The most active players are AstraZeneca, Neurim Pharmaceuticals Ltd., Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 6 therapies are approved with 5 more in late-stage development.

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

15/100

Mech. Concentration

29/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

14

clinical trials

Completed8 · 57%
Unknown status4 · 29%
Not yet recruiting2 · 14%

Trial Activity

14 trials

Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis
Completed··Phase 4·NCT02959229·180 enrolled
Antibiotic Therapy for Early Onset Neonatal Sepsis
Unknown status·SShandong University·N/A·NCT03932123·500 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)